BlossomHill Therapeutics Doses Patients in the First Cohort of the Phase 1/2 SOLARA Clinical Trial of BH-30643 for EGFR- and HER2-Mutated Non-Small Cell Lung Cancerwebsite2646Jan 231 min readhttps://www.businesswire.com/news/home/20250122706462/en/BlossomHill-Therapeutics-Doses-Patients-in-the-First-Cohort-of-the-Phase-12-SOLARA-Clinical-Trial-of-BH-30643-for-EGFR--and-HER2-Mutated-Non-Small-Cell-Lung-Cancer
https://www.businesswire.com/news/home/20250122706462/en/BlossomHill-Therapeutics-Doses-Patients-in-the-First-Cohort-of-the-Phase-12-SOLARA-Clinical-Trial-of-BH-30643-for-EGFR--and-HER2-Mutated-Non-Small-Cell-Lung-Cancer
xMEMS XMC-2400: The World’s First 1mm-Thin Active Micro Cooling Fan on a ChipxMEMS Introduces 1mm-Thin Active Micro Cooling “Fan on a Chip”
Repligen Announces Agreement to Acquire Chromatography Innovator TanttiRepligen Announces Agreement to Acquire Chromatography (globenewswire.com)
Alamar Biosciences and Biomarkers of Aging Consortium Join Forces to Revolutionize Longevity Researchhttps://www.prnewswire.com/news-releases/alamar-biosciences-and-biomarkers-of-aging-consortium-join-forces-to-revolutionize-longevity-res...
Comments